In addition, EGFR and RAS mutations are known to confer radioresistance in colorectal cancers, and some studies have investigated adding tyrosine kinase inhibitor or monoclonal antibody as a radiosensitizer [40,41,42,43,44]. The gene discussed is EGFR; the disease is colorectal cancer.